Credit Suisse restated their underperform rating on shares of AstraZeneca (LON:AZN) in a report issued on Thursday, American Banking and Market News reports. They currently have a GBX 3,220 ($53.07) target price on the stock. Credit Suisse has also updated their ratings on a number of other stocks in the last week. The firm reiterated […]
AstraZeneca’s “Underperform” Rating Reaffirmed at Credit Suisse (AZN) is a post from: Zolmax
The post AstraZeneca’s “Underperform” Rating Reaffirmed at Credit Suisse (AZN) appeared first on Zolmax.